Nadler J, Zipser R D, Coleman R, Horton R
J Clin Endocrinol Metab. 1983 Jun;56(6):1260-5. doi: 10.1210/jcem-56-6-1260.
The effect of vasoconstrictive agonists and their nonpressor analogs on renal prostaglandin production was investigated in normal subjects maintained on constant diets. Arginine vasopressin (AVP), 10 U, desamino-d arginine vasopressin (dDAVP), 4 micrograms, angiotensin II (AII), 5 ng/kg . min, des-Asp angiotensin II (AIII), 5 ng/kg . min, norepinephrine (NE), 0.1 microgram/kg . min, and NE plus phenoxybenzamine (PHB), 0.8 mg/kg, were administered on separate days. Prostaglandin E2 (PGE2) and the stable prostacyclin metabolite, 6 keto prostaglandin F1 alpha were measured in 4-h urine collections by procedures with high resolution chromatography and RIA using highly specific antisera. AVP and dDAVP similarly reduced urine volume and increased urine osmolality. AII, AIII, NE, and NE + PHB did not alter basal urine volume, osmolality, creatinine, or electrolyte excretion. Blood pressure was similarly increased by AII and NE infusions (23 +/- 3 vs. 19 +/- 2 (SE) mm Hg). AVP and AII increased only PGE2 excretion (61 +/- 8 to 151 +/- 34 ng/4 h for AVP, and 38.7 +/- 7 to 75 +/- 19 ng/4 h for AII, P less than 0.05). The nonpressor analogs, dDAVP and AIII, had no effect on urinary prostaglandin excretion. In contrast, NE increased both PGE2 (from 38.7 +/- 7 to 74.5 +/- 12 ng/4 h, P less than 0.02) and 6 keto prostaglandin F1 alpha (from 34.6 +/- 8 to 56.1 +/- 9 ng/4 h, P less than 0.02). alpha-Blockade with PHB totally abolished the NE-induced systemic pressor and prostaglandin stimulatory effect. These data suggest that renal PGE2 and prostacyclin are not altered in parallel by vasoactive stimuli. PGE2 appears to be released in response to agents that induce renal vasoconstriction and reduced renal blood flow whereas renal prostacyclin excretion is stimulated by an adrenergic agonist via alpha-receptor activation and not vasoconstriction per se.
在维持恒定饮食的正常受试者中,研究了血管收缩激动剂及其非升压类似物对肾前列腺素生成的影响。分别于不同日期给予精氨酸加压素(AVP,10 U)、去氨基 - d - 精氨酸加压素(dDAVP,4微克)、血管紧张素II(AII,5 ng/kg·min)、去天冬氨酸血管紧张素II(AIII,5 ng/kg·min)、去甲肾上腺素(NE,0.1微克/kg·min)以及NE加酚苄明(PHB,0.8 mg/kg)。通过高分辨率色谱法和使用高特异性抗血清的放射免疫分析法,测定4小时尿液收集物中的前列腺素E2(PGE2)和稳定的前列环素代谢产物6 - 酮 - 前列腺素F1α。AVP和dDAVP同样减少尿量并增加尿渗透压。AII、AIII、NE以及NE + PHB未改变基础尿量、渗透压、肌酐或电解质排泄。AII和NE输注同样使血压升高(分别为23±3与19±2(SE)mmHg)。AVP和AII仅增加PGE2排泄(AVP从61±8 ng/4 h增至151±34 ng/4 h,AII从38.7±7 ng/4 h增至75±19 ng/4 h,P < 0.05)。非升压类似物dDAVP和AIII对尿前列腺素排泄无影响。相反,NE增加PGE2(从38.7±7 ng/4 h增至74.5±12 ng/4 h,P < 0.02)以及6 - 酮 - 前列腺素F1α(从34.6±8 ng/4 h增至56.1±9 ng/4 h,P < 0.02)。用PHB进行α - 阻断完全消除了NE诱导的全身升压和前列腺素刺激作用。这些数据表明,血管活性刺激不会使肾PGE2和前列环素平行改变。PGE2似乎是对诱导肾血管收缩和肾血流量减少的药物作出反应而释放,而肾前列环素排泄是由肾上腺素能激动剂通过α - 受体激活而非血管收缩本身刺激产生的。